Reyes Arranz

Reyes Arranz

Auto-generated profile, based on publicly available information

Reyes Arranz

Hospital La Princesa, Madrid, Spain

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2004 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JRJ. Rodriguez
J. Rodriguez
MCM. D. Caballero
M. D. Caballero
AGA. Gutierrez
A. Gutierrez
CSCarlos Solano
Carlos Solano
RAR. Arranz
R. Arranz
ECE. Conde
E. Conde
Background: Here we evaluate the results of high-dose chemotherapy and autologous stem-cell transplantation (HDC/ASCT) in 114 patients included in the GEL/TAMO registry between January 1990 and December 1999 with diffuse large B-cell lymphoma who failed to achieve complete remission (CR) with front-line conventional chemotherapy. Patients and methods: Sixty-eight per cent had a partial response (PR) and 32% failed to respond to front-line therapy. At transplant, 35% were chemoresistant and 29% had two to three adjusted International Prognostic Index (a-IPI) risk factors. Results: After HDC/ASCT, 57 (54%) of 105 patients evaluable for response achieved a CR, 16 (15%) a PR and 32 (30%) failed. Nine patients were not assessed for response because of early death due to toxicity. With a median follow-up of 29 months for alive patients, the survival at 5 years is 43%, with a disease-free survival for complete responders of 63%. The lethal toxicity was 8%. Multivariate analysis revealed a-IPI and chemoresistance to be predicting factors. Conclusions: Our results show that one-third of patients who do not obtain a CR to front-line chemotherapy may be cured of their disease with HDC/ASCT. However, most chemoresistant patients pretransplant failed this therapy. For this population, as well as for those who presented with adverse factors of the a-IPI, pretransplant novel therapeutic modalities need to be tested.

10 June 2013 in Haematologica
Verified
Journal Article
Closed access
RAR. Arranz
R. Arranz
AGA. Garcia-Noblejas
A. Garcia-Noblejas
CGC. Grande
C. Grande
JCJ. Cannata-Ortiz
J. Cannata-Ortiz
JSJ. J. Sanchez
J. J. Sanchez
DCD. Caballero
D. Caballero
The prognosis for fit patients with mantle cell lymphoma has improved with intensive strategies. Currently, the role of maintenance/consolidation approaches is being tested as relapses continue to appear. In this trial we evaluated the feasibility, safety and efficacy of rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine followed by consolidation with (90)Y-ibritumomab tiuxetan. Patients received six cycles followed by a single dose of (90)Y-ibritumomab tiuxetan. Thirty patients were enrolled; their median age was 59 years. Twenty-four patients finished the induction treatment, 23 achieved complete remission (77%, 95% confidence interval 60-93) and one patient had progressive disease (3%). Eighteen patients (60%), all in complete remission, received consolidation therapy. In the intent-to-treat population, failure-free, progression-free and overall survival rates at 4 years were 40% (95% confidence interval 20.4-59.6), 52% (95% confidence interval 32.4-71.6) and 81% (95% confidence interval 67.28-94.72), respectively. For patients who received consolidation, failure-free and overall survival rates were 55% (95% confidence interval 31.48-78.52) and 87% (95% confidence interval 70-100), respectively. Hematologic toxicity was significant during induction and responsible for one death (3.3%). After consolidation, grade 3-4 neutropenia and thrombocytopenia were observed in 72% and 83% of patients, with a median duration of 5 and 12 weeks, respectively. Six (20%) patients died, three due to secondary malignancies (myelodysplastic syndrome and bladder and rectum carcinomas). In conclusion, in our experience, rituximab-hyperCVAD alternated with rituximab-methotrexate-cytarabine and followed by consolidation with (90)Y-ibritumomab tiuxetan was efficacious although less feasible than expected. The unacceptable toxicity observed, especially secondary malignancies, advise against the use of this strategy. clinical.gov identifier: NCT2005-004400-37.

1 October 2000
Verified
Journal Article
Closed access
EGE Granados
E Granados
RCR De La Cámara
R De La Cámara
LML Madero
L Madero
MDMiguel A. Diaz
Miguel A. Diaz
PMP Martín-Regueira
P Martín-Regueira
JFJ M Fernández-Rañada
J M Fernández-Rañada

18 December 2007 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RAReyes Arranz
Reyes Arranz
ECEulogio Conde
Eulogio Conde
CGCarlos Grande
Carlos Grande
MMMaria Victoria Mateos
Maria Victoria Mateos
MGMarco Gandarillas
Marco Gandarillas
T(The Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (Gel–Tamo)
The Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (Gel–Tamo)

1 November 1996
Verified
Journal Article
Closed access
JGJ J Gil-Fernández
J J Gil-Fernández
AAA Alegre
A Alegre
MFM J Fernández-Villalta
M J Fernández-Villalta
IPI Pinilla
I Pinilla
VGV Gómez García
V Gómez García
JFJ M Fernández-Rañada
J M Fernández-Rañada

24 May 2017 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
AGA. García-Noblejas
A. García-Noblejas
JCJ. Cannata-Ortiz
J. Cannata-Ortiz
ECE. Conde
E. Conde
EBEVA MARIA GONZALEZ BARCA
EVA MARIA GONZALEZ BARCA
Norma C. GutiérrezNorma C. Gutiérrez
Norma C. Gutiérrez
RAR. Arranz
R. Arranz